selective oral Wee1 kinase inh. (300 mg QD)

Ph. II candidate for uterine serous carcinoma

from literature starting point

Journal of Medicinal Chemistry

Zentalis Pharmaceuticals, San Diego, CA, USA


The Zentalis Wee1 inhibitor, ZN-c3, is a highly selective kinase inhibitor that is currently being evaluated in Ph. II clinical trials in adult women with recurrent or persistent uterine serous…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: